Cite this: *Chem. Commun.*, 2019, 55, 14777

Received 31st October 2019,
Accepted 8th November 2019

DOI: 10.1039/c9cc08518a

rsc.li/chemcomm

A stapled chromogranin A-derived peptide is a potent dual ligand for integrins $\alpha v\beta 6$ and $\alpha v\beta 8$ †

Francesca Nardelli,^{‡a} Michela Ghitti,^{‡a} Giacomo Quilici,^{‡a} Alessandro Gori,^{‡b} Qingqiong Luo,^{‡c} Andrea Berardi,^{‡a} Angelina Sacchi,^{‡a} Matteo Monieri,^{‡a} Greta Bergamaschi,^{‡b} Wolfgang Bermel,^d Fuxiang Chen,^{‡c} Angelo Corti,^{‡a,e} Flavio Curnis^{‡a} and Giovanna Musco^{‡a}

Combining 2D STD-NMR, computation, biochemical assays and click-chemistry, we have identified a chromogranin-A derived compound (5) that has high affinity and bi-selectivity for $\alpha v\beta 6$ and $\alpha v\beta 8$ integrins and is stable in microsomal preparations. 5 is suitable for nanoparticle functionalization and delivery to cancer cells, holding promise for diagnostic and/or therapeutic applications.

Integrins $\alpha v\beta 6$ and $\alpha v\beta 8$ are epithelial-specific cell-adhesion receptors, playing a fundamental role in pro-fibrotic cytokine transforming growth factor beta (TGF β) activation in fibrosis.¹ They are also highly expressed during tissue remodelling, wound healing, and cancer cell migration, invasion and growth, whereby over-expression correlates with poor patient prognosis.^{2,3} Hence, targeting of cells highly expressing one or both integrins through high affinity ligands with dual specificity and reduced off-targeting effects may represent a valid, yet poorly explored pharmacological strategy against cancer and/or fibrosis. $\alpha v\beta 6$ and $\alpha v\beta 8$ are structurally⁴ and functionally related,³ albeit $\alpha v\beta 8$ ^{5–7} and its inhibition is far less studied than $\alpha v\beta 6$.^{8–13} Both integrins bind to arginine-glycine-aspartate (RGD) containing extracellular matrix proteins, whereby selective recognition occurs through the LXXL/I motif contiguous to the RGD sequence (RGDLXXL/I),^{5,14} which folds into one-helical turn upon binding to the receptor, thereafter engaging in specific lipophilic interactions with the hydrophobic pocket of the $\beta 6$ or $\beta 8$ subunit.^{5,15–18} We have previously shown that human chromogranin A (CgA), a neurosecretory protein involved in the cardiovascular system, metabolism, and tumor physiology^{19,20} regulation is a natural

ligand of $\alpha v\beta 6$.²¹ A CgA-derived peptide (residues 39–63) (**1**) also recognizes $\alpha v\beta 6$ with nanomolar affinity and high selectivity (K_i : 15.5 ± 3.2 nM) (Table 1), herewith regulating $\alpha v\beta 6$ -dependent keratinocyte adhesion, proliferation, and migration.²¹ Notably, **1** harbours a degenerate RGDLXXL/I motif, with a glutamate replacing a leucine after the RGD sequence (position $D + 1$, RGDEXXL) (Fig. S1, ESI†). Prompted by this peculiarity, we investigated the structural determinants of **1**/ $\alpha v\beta 6$ interaction by heteronuclear 2D-NMR STD methods and docking calculations. Intriguingly, while **1** is highly specific for $\alpha v\beta 6$, reconstitution of the canonical RGDLXXL motif, combined with a click-chemistry stapling strategy results in a novel potent ligand suitable for the dual targeting of $\alpha v\beta 6$ / $\alpha v\beta 8$ for diagnostic and therapeutic purposes.

We studied the conformation of recombinant peptide **1** in physiological conditions by homonuclear and heteronuclear multidimensional NMR. Peptide **1** was expressed in *E. coli* as an insoluble fusion partner of ketosteroid isomerase, and subsequently cleaved with CNBr and purified by HPLC.²² Recombinant ¹³C/¹⁵N **1** displays the typical NOE pattern of the α -helical conformation between residue E46 to K59, with both termini being unstructured (Fig. 1a, c and Tables S1, S2, ESI†). Accordingly, the helical segment and both termini display relatively high (~ 0.5) and very low (< 0.3) heteronuclear NOE values, respectively (Fig. 1d). The RGD motif adjacent to the α -helix is relatively flexible, and thus well suited to adapt inside the integrin-binding pocket (Fig. 1a). The first three turns of the post-RGD helix are amphipathic, with I48, L49, I51, L52 and E46, R47, S50 on opposite sides (Fig. 1a and b). Peptide **1** propensity to adopt an α -helical conformation is in line with previous NMR studies on CgA_{47–66}, an antifungal CgA-derived peptide, all-helical in the helix-promoting solvent tri-fluoro-ethanol, TFE.²³ To gain molecular insights into the **1**/ $\alpha v\beta 6$ complex and group selective information on the interaction, we performed in the presence of the extracellular region of recombinant human $\alpha v\beta 6$ (4 μ M) 1D-¹H saturation transfer difference (STD) spectroscopy (Fig. S2a, ESI†) and heteronuclear two-dimensional STD experiments,²⁴ exploiting isotopically labelled (¹³C/¹⁵N) recombinant peptide **1** (0.5 mM) (Fig. 2a and Fig. S2b, ESI†). The 2D-STD-¹H-¹⁵N-HSQC resolved peak ambiguities in the 1D-¹H STD spectrum and

^a IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
E-mail: corti.angelo@hsr.it, curnis.flavio@hsr.it, ghitti.michela@hsr.it, musco.giovanna@hsr.it

^b Istituto di Chimica del Riconoscimento Molecolare, C.N.R., Via Mario Bianco 9, 20131 Milan, Italy

^c Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China

^d Bruker BioSpin GmbH, Silberstreifen 4, Rheinstetten, 76287, Germany

^e Vita Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9cc08518a

‡ Current address: University of Pisa, Via Moruzzi 13, I-56124 Pisa, Italy.

Table 1 Inhibition constants (K_i , nM) and the associated standard error of the mean of compounds **1–6** for integrins as determined by the competitive binding assay (ESI)

Code	Peptide ^a	$\alpha v \beta 6$		$\alpha v \beta 8$		$\alpha 5 \beta 1$		$\alpha v \beta 5$		$\alpha v \beta 3$	
		<i>n</i> ^b	K_i	<i>n</i>	K_i	<i>n</i>	K_i	<i>n</i>	K_i	<i>n</i>	K_i
1	FETLRGDERILSRHQNLKELQD	6	15.5 ± 3.2	6	7663 ± 1704	4	9206 ± 1810	5	3600 ± 525	4	2192 ± 690
2	FETLRGEEILSRHQNLKELQD ^c	1	$> 50\,000$	1	$> 50\,000$	1	$> 50\,000$	1	$> 50\,000$	1	$> 50\,000$
3	FETLRGDERILSRH	4	277 ± 74^d	1	31 174	1	10 110	1	2039	1	1250
4	FETLRGDLRLSRHQNLKELQD	11	1.6 ± 0.3^e	6	8.5 ± 3.7^f	3	924 ± 198	4	2405 ± 592	3	1928 ± 226
5	FETLRGDLRLSRX ₂ QNLX ₂ KELQD	7	0.6 ± 0.1^g	6	3.2 ± 1.2^h	3	1310 ± 389	4	2741 ± 615	3	2453 ± 426
6	NAVPNLRGDLQVLAQKVART	8	0.9 ± 0.2	6	69 ± 12	5	2317 ± 10	5	$15\,449 \pm 2418$	3	$26\,197 \pm 7387$

^a Mutated residues and triazole-stapled residues (X_1 and X_2 , as defined in Fig. S6a, ESI). ^b *n*, number of independent experiments (each performed with 6 different concentrations of competitor in technical duplicates). ^c K_i of 2 as determined in ref. 21. ^d *P* value versus 1: *p* < 0.05; two tailed *t* test. ^e *P* value versus 1: *p* < 0.001, two tailed *t* test. ^f *P* value versus 1: *p* < 0.01, two tailed *t* test. ^g *P* value versus 4: *p* < 0.05; two tailed *t* test. ^h *P* value versus 4: *p* > 0.1; two tailed *t* test.

Fig. 1 Solution structure of **1**. (a) Representation of the 15 lowest energy NMR structures (pdb code: 6R2X) aligned on E46–N56 backbone atoms with the RGD motif in orange and I48, L49, I51 and L52 in green. (b) Helical wheel projection of residue E46–L52 with hydrophobic residues in green. (c) Scheme of medium and short NOEs relevant for secondary structure identification. Height of the boxes is proportional to NOE intensities. (d) Sequence specific backbone (^1H)– ^{15}N NOEs with elements of secondary structure indicated on the top.

provided residue-specific STD effect values. Hydrophobic amino acids (I48, L49, I51, and L52) of the post-RGD helix displayed the strongest STD% values²⁴ (> 75%), suggesting their important contribution to receptor binding (Fig. 2b). Intense STD effects of the methyl groups of branched amino acids in 2D-STD- ^1H - ^{13}C -HSQC corroborated their involvement in the interaction, though signal overlap hampered their quantification for epitope mapping (Fig. S2b, ESI†). To exclude false positive effects, we spiked recombinant peptide **1** with bovine serum albumin as a negative control: no interaction occurred, and we did not observe any STD signal (Fig. S3a and b, ESI†). 2D-STD- ^1H - ^{15}N -HSQC performed with $\alpha v \beta 6$ pre-incubated with 20 mM of EDTA resulted

in depletion of the STD effects, thus confirming the presence of the electrostatic clamp between the receptor metal ion and the aspartate side chain of the RGD motif (Fig. S3c, ESI†). This result is in line with competitive binding assays using a peptide with RGE instead of RGD (**2**), yielding a $K_i > 50\ \mu\text{M}$ (Table 1). Next, we incorporated the 2D-STD experimental information in data driven docking calculations (HADDOCK2.2)²⁵ to determine the binding mode of **1** with the extracellular head of $\alpha v \beta 6$ (PDB: 5FFO).¹⁶ The model highlights receptor–ligand interactions highly reminiscent of those observed for the proTGF- $\beta 1/\alpha v \beta 6$ complex (Fig. 2c and Fig. S4a, ESI†).¹⁶ On one hand, the guanidinium of R43 forms electrostatic interactions with Asp218 $_{\alpha v}$ and Asp150 $_{\alpha}$; on the other hand, the carboxylate of D45 coordinates the metal ion-dependent adhesion site (MIDAS) and interacts with the amide of Ser127 $_{\beta 6}$ and Asn218 $_{\beta 6}$. I48, L49, I51, and L52, located respectively on the second and the third turn of the post-RGD amphipathic α -helix, make extensive hydrophobic interactions with $\beta 6$ residues of the specificity determining loops (SDLs), including Ala126 $_{\beta 6}$, Asp129 $_{\beta 6}$ (SDL1), Ile183 $_{\beta 6}$, Tyr185 $_{\beta 6}$ (SDL2), and Ala217 $_{\beta 6}$ (SDL3) (Fig. 2c), thus explaining the selectivity of **1** towards $\alpha v \beta 6$ with respect to the other αv integrins (Table 1). Since in our model residue E46 points towards the receptor interior, we reasoned that the preformed α -helix of **1** might entropically compensate the unfavourable electrostatic contribution of the negative charge within the hydrophobic binding pocket. Thus, we synthesized a shorter peptide containing the hydrophobic residues important for the interaction, without ten C-terminal residues supposed to be crucial for the helical propensity (**3**). Indeed, **3** showed a drastic reduction both in α -helical content (Fig. S5, ESI†) and binding to $\alpha v \beta 6$ (K_i : $277 \pm 77\ \text{nM}$) (Table 1), supporting the notion that the stability of the preformed four-turn amphipathic helix adjacent to the RGD motif is fundamental for effective $\alpha v \beta 6$ recognition.^{18,26} We next predicted that restoring the canonical LXXL motif might increase the affinity of **1** for $\alpha v \beta 6$. Indeed, the replacement in position *D* + 1 of E46 with a leucine (**4**) lowered the K_i by one order of magnitude (K_i : $1.6 \pm 0.3\ \text{nM}$) (Table 1). Intriguingly, reconstitution of the LXXL motif transforms **4** into a bi-selective ligand able to bind also $\alpha v \beta 8$ (K_i : $8.5 \pm 3.7\ \text{nM}$).

Structurally, $\alpha v \beta 6$ and $\alpha v \beta 8$ share a similar wide lipophilic SDL pocket, suitable for hydrophobic interactions with the

Fig. 2 Interaction of $\alpha v\beta 6$ with **1** and **5**. (a) 2D-STD- ^1H - ^{15}N -HSQC experiment performed on ^{15}N labelled peptide **1** (0.5 mM) in the presence of recombinant extracellular $\alpha v\beta 6$ (4 μM), off-resonance (left) and difference spectra (right); asterisks indicate overlapped signals; Hsl (Homoserine lactone). (b) Residue-specific STD%, as defined in the ESI†; asterisks indicate overlapping signals. Residues with STD% > 75% are mapped on the 3D structure. (c) HADDOCK model of **1** (blue cartoon) and (d) **5** (pink cartoon) in complex with $\alpha v\beta 6$. Ligand and receptor residues involved in the interaction, E46 in **1** and the triazole-containing stapled residues in **5** are shown in sticks. Sequence and secondary structure of **1** and **5** are shown on the top. Interacting residues are highlighted in bold.

amphiphilic helix of **4**. Of note, minor changes in the shape and in the sequence of the SDL loops, such as the presence in SDL2 of K170 and T171 in $\beta 6$ and S159 and I160 in $\beta 8$, respectively (Fig. S4c, ESI†), might explain why the presence of E46 in the ligand is tolerated by $\beta 6$ and not by $\beta 8$ (Table 1). Prompted by these results, we hypothesized that chemical stabilization of the α -helix *via* stapling, *i.e.* “side-chain-to-side-chain” cyclization,²⁷ might further improve the binding properties of **4**. Based on a 5/ $\alpha v\beta 6$ model (Fig. 2d) we constrained this peptide *via* a triazole-bridged macrocyclic scaffold between residues in position 54 (propargylglycine) and 58 (azidolysine) through copper-catalyzed azide-alkyne cycloaddition (**5**) (Fig. S6a and b, ESI†).^{27,28}

Indeed, the structural constraint boosted the α -helical content of **5**, compared to **4**, (Fig. S6c, ESI†), resulting in a significant 2 to 3-fold increase in $\alpha v\beta 6$ binding (K_i : 0.6 ± 0.1 nM), comparable to the reference compound foot and mouth disease virus-derived peptide A20FMDV2 (**6**, K_i : 0.9 ± 0.2 nM) (Table 1).^{11,18} Stapling maintained nM binding to $\alpha v\beta 8$ (K_i : 3.2 ± 1.2 nM), thus generating, to the best of our knowledge, the strongest bi-selective ligand for $\alpha v\beta 6/\alpha v\beta 8$ described so far.^{6,29} Importantly, peptides **1**, **4**, **5** and **6** were able to recognize $\alpha v\beta 6$ in its physiological context, as they bound $\alpha v\beta 6$ expressed on the cell-surface of human bladder 5637 cells and human keratinocytes (HaCat) with a relative binding potency similar to that observed with the purified recombinant $\alpha v\beta 6$ (Fig. S7, ESI†). **5** was the most effective with an activity comparable to the reference compound **6** (Fig. 3a and Fig. S8, ESI†).³⁰ Notably, both **4** and **5** were not cytotoxic *in vitro* (Fig. S9, ESI†). To assess whether **5** was suitable for nanoparticle functionalization and delivery to cancer cells, we coupled it to fluorescent quantum dot nanoparticles *via* an N-terminal cysteine (5-Qdot) and evaluated its binding to 5637 cells. Flow cytometry and fluorescence microscopy showed that 5-Qdot, but not a control nanoconjugate without the targeting ligand (*Qdot), bound the cells, indicating that **5** maintains its receptor-tailored properties also after conjugation (Fig. 3b and c). Finally, ELISA stability assays of **4** and **5** conjugated to horseradish peroxidase (**4**-HRP, **5**-HRP) in human serum showed that >50% of **4**-HRP and **5**-HRP were still present after 24 hours of incubation at 37 °C, supporting their

Fig. 3 Binding of CgA-derived peptides to human bladder cancer 5637 cells. (a) Effect of **1**, **4**, **5** and **6** on the binding of anti- $\alpha v\beta 6$ mAb 10D5 to 5637 cells. Antibody binding quantification by flow cytometry analysis (FACS) (representative experiment, see also Fig. S8a, ESI†). Compounds were mixed with mAb 10D5 and added to cells; mAb binding was detected by FACS and inhibitory concentration (IC_{50} , mean $\pm$ SEM) was determined. Each point is in duplicate. (b) Binding of 5-Qdot or *Qdot (control) to 5637 cells as measured by FACS. Representative FACS (left and middle) and quantification of Qdot binding (right) (circles: mean $\pm$ SD of duplicates). (c) Representative fluorescence bioimaging of 5637 cells incubated with 5-Qdot, *Qdot or diluent. Magnification 40x; red, Qdot; blue, nuclear staining with DAPI.

proteolytic stability in biological fluids (Fig. S10, ESI†). Importantly, stability assays with mouse liver microsomes showed that 5 was more stable than 4 ($t_{1/2}$ = 4.3 h and $t_{1/2}$ = 1.3 h, respectively, Fig. S11, ESI†).

In conclusion, NMR experiments allied to computational and biochemical methods elucidated the molecular details at the basis of $\alpha\nu\beta 6$ recognition by CgA-derived peptides, giving first hints on the interaction between $\alpha\nu\beta 6$ and CgA.¹⁹ The entropic gain, derived from the preformed four-turns α -helix adjacent to the RGD motif, combined to the hydrophobic interactions between residues in position $D + 3$, $D + 4$, and $D + 7$ and the $\beta 6$ subunit, largely compensate the unfavourable electrostatic repulsion of E46 in position $D + 1$. Thus, the natural $\alpha\nu\beta 6$ recognition motif RGDLLXL is less restrictive than previously supposed and can be extended to RGDEXXL, provided that the helix adjacent to RGD is preformed and presents an extensive hydrophobic surface for $\alpha\nu\beta 6$ interaction. Importantly, the complex model inspired the design of novel peptides, including a stapled one with high stability, sub-nanomolar affinity and bi-selectivity for $\alpha\nu\beta 6/\alpha\nu\beta 8$ integrins. These molecules, derived from a human protein, may represent useful and safer tools for the ligand-directed targeted delivery of diagnostic and therapeutic compounds and nanodevices to epithelial cancers with high expression of $\alpha\nu\beta 6$ and/or $\alpha\nu\beta 8$, such as oral and skin squamous cell carcinoma.³¹ Furthermore, in light of the roles of both $\alpha\nu\beta 6$ and $\alpha\nu\beta 8$ in TGF β maturation and fibrosis,¹ the dual targeting ability of these compounds could be also conveniently used to develop anti-fibrotic drugs and tracer devices, thus adding to the still limited number of small molecules able to specifically recognize these integrins.

The authors thank M. Alfano for helpful discussion. This work was supported by EU Horizon 2020 (801126, EDIT) and AIRC (IG-19220, IG-21440, 22737). F. N. conducted this study within her PhD course at S Raffaele University, Milan.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 K. P. Conroy, L. J. Kitto and N. C. Henderson, *Cell Tissue Res.*, 2016, **365**, 511–519.
- 2 L. Koivisto, J. Bi, L. Häkkinen and H. Larjava, *Int. J. Biochem. Cell Biol.*, 2018, **99**, 186–196.
- 3 M. Nieberler, U. Reuning, F. Reichart, J. Notni, H. Wester, M. Schwaiger, M. Weinmüller, A. Räder, K. Steiger and H. Kessler, *Cancers*, 2017, **9**, 116.
- 4 I. D. Campbell and M. J. Humphries, *Cold Spring Harb. Perspect. Biol.*, 2011, **3**, 1–14.
- 5 A. Ozawa, Y. Sato, T. Imabayashi, T. Uemura, J. Takagi and K. Sekiguchi, *J. Biol. Chem.*, 2016, **291**, 11551–11565.
- 6 F. Reichart, O. V. Maltsev, T. G. Kapp, A. F. B. Räder, M. Weinmüller, U. K. Marelli, J. Notni, A. Wurzer, R. Beck, H.-J. Wester, K. Steiger, S. Di Maro, F. S. Di Leva, L. Marinelli, M. Nieberler, U. Reuning, M. Schwaiger and H. Kessler, *J. Med. Chem.*, 2019, **62**, 2024–2037.
- 7 A. Cormier, M. G. Campbell, S. Ito, S. Wu, J. Lou, J. Marks, J. L. Baron, S. L. Nishimura and Y. Cheng, *Nat. Struct. Mol. Biol.*, 2018, **25**, 698–704.
- 8 O. V. Maltsev, U. K. Marelli, T. G. Kapp, F. S. Di Leva, S. Di Maro, M. Nieberler, U. Reuning, M. Schwaiger, E. Novellino, L. Marinelli and H. Kessler, *Angew. Chem., Int. Ed.*, 2016, **55**, 1535–1539.
- 9 F. S. Di Leva, S. Tomassi, S. DiMaro, F. Reichart, J. Notni, A. Dangi, U. K. Marelli, D. Brancaccio, F. Merlino, H. J. Wester, E. Novellino, H. Kessler and L. Marinelli, *Angew. Chem., Int. Ed.*, 2018, **44**, 14645–14649.
- 10 M. Civera, D. Arosio, F. Bonato, L. Manzoni, L. Pignataro, S. Zanella, C. Gennari, U. Piarulli and L. Belvisi, *Cancers*, 2017, **9**, 128.
- 11 S. H. Hausner, D. DiCara, J. Marik, J. F. Marshall and J. L. Sutcliffe, *Cancer Res.*, 2007, **67**, 7833–7840.
- 12 R. H. Kimura, R. Teed, B. J. Hackel, M. A. Pysz, C. Z. Chuang, A. Sathirachinda, J. K. Willmann and S. S. Gambhir, *Clin. Cancer Res.*, 2012, **18**, 839–849.
- 13 A. Altmann, M. Sauter, S. Roesch, W. Mier, R. Warta, J. Debus, G. Dychkoff, C. Herold-Mende and U. Haberkorn, *Clin. Cancer Res.*, 2017, **23**, 4170–4180.
- 14 S. Kraft, B. Diefenbach, R. Mehta, A. Jonczyk, G. A. Luckenbach and S. L. Goodman, *J. Biol. Chem.*, 1999, **274**, 1979–1985.
- 15 X. Dong, N. E. Hudson, C. Lu and T. A. Springer, *Nat. Struct. Mol. Biol.*, 2014, **21**, 1091–1096.
- 16 X. Dong, B. Zhao, R. E. Iacob, J. Zhu, A. C. Koksall, C. Lu, J. R. Engen and T. A. Springer, *Nature*, 2017, **542**, 55–59.
- 17 A. Kotecha, Q. Wang, X. Dong, S. L. Ilca, M. Ondiviola, R. Zihe, J. Seago, B. Charleston, E. E. Fry, N. G. A. Abrescia, T. A. Springer, J. T. Huiskonen and D. I. Stuart, *Nat. Commun.*, 2017, **8**, 15408–15416.
- 18 D. DiCara, C. Rapisarda, J. L. Sutcliffe, S. M. Violette, P. H. Weinreb, I. R. Hart, M. J. Howard and J. F. Marshall, *J. Biol. Chem.*, 2007, **282**, 9657–9665.
- 19 A. Corti, F. Marcucci and T. Bachetti, *Pflugers Arch. Eur. J. Physiol.*, 2018, **470**, 199–210.
- 20 K. B. Helle, M. H. Metz-Boutigue, M. C. Cerra and T. Angelone, *Pflugers Arch. Eur. J. Physiol.*, 2018, **470**, 143–154.
- 21 F. Curnis, A. M. Gasparri, R. Longhi, B. Colombo, S. D'Alessio, F. Pastorino, M. Ponzoni and A. Corti, *Cell. Mol. Life Sci.*, 2012, **69**, 2791–2803.
- 22 J. L. Wagstaff, M. J. Howard and R. A. Williamson, *Mol. Biosyst.*, 2010, **6**, 2380–2385.
- 23 K. Lugardon, S. Chasserot-Golaz, A.-E. Kieffer, R. Maget-Dana, G. Nullans, B. Kieffer, D. Aunis and M.-H. Metz-Boutigue, *J. Biol. Chem.*, 2001, **276**, 35875–35882.
- 24 J. L. Wagstaff, S. Vallath, J. F. Marshall, R. A. Williamson and M. J. Howard, *Chem. Commun.*, 2010, **46**, 7533.
- 25 C. Dominguez, R. Boelens and A. M. J. J. Bonvin, *J. Am. Chem. Soc.*, 2003, **125**, 1731–1737.
- 26 Y. K. S. Man, D. DiCara, N. Chan, S. Vessillier, S. J. Mather, M. L. Rowe, M. J. Howard, J. F. Marshall and A. Nissim, *PLoS One*, 2013, **8**, e70452.
- 27 Y. S. Tan, D. P. Lane and C. S. Verma, *Drug Discov. Today*, 2016, **21**, 1642–1653.
- 28 A. Gori, C.-I. A. Wang, P. J. Harvey, K. J. Rosengren, R. F. Bhola, M. L. Gelmi, R. Longhi, M. J. Christie, R. J. Lewis, P. F. Alewood and A. Brust, *Angew. Chem., Int. Ed.*, 2015, **54**, 1361–1364.
- 29 T. G. Kapp, F. Rechenmacher, S. Neubauer, O. V. Maltsev, E. A. Cavalcanti-Adam, R. Zarka, U. Reuning, J. Notni, H. J. Wester, C. Mas-Moruno, J. Spatz, B. Geiger and H. Kessler, *Sci. Rep.*, 2017, **7**, 1–12.
- 30 X. Huang, J. Wu, S. Spong and D. Sheppard, *J. Cell Sci.*, 1998, **111**, 2189–2195.
- 31 H. Ahmedah, L. Patterson, S. Shnyder and H. Sheldrake, *Cancers*, 2017, **9**, 56.